Bernhard Kirschbaum
Direttore/Membro del Consiglio presso REDX PHARMA PLC
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
James Robert Mead | M | 46 | 6 anni | |
Andrew Booth | M | - | 9 anni | |
Karen Uhlmann | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 anni |
Peter Presland | M | 75 | 7 anni | |
Robert Fischer | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 anni |
Leent Ben Van | M | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 16 anni |
Christian Tidona | M | - |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | 11 anni |
Lisa Anson | F | - | 6 anni | |
Wolf-Hagen Schunck | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 11 anni |
Henk Johan Streefkerk | M | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 2 anni |
Peter de Haan | M | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 16 anni |
Christian Schetter | M | 60 |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 5 anni |
Yvonne Stappenbeck | F | - |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | - |
Aric Orbach | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 2 anni |
Keren Kocshitzki | F | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 6 anni |
John Isaac | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Nischal Hindia | M | - | - | |
Steve Hitchcock | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Harry Raftopoulos | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Gerhard Ries | M | - |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | - |
Modi Teicher | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 2 anni |
Tetsuyuki Maruyama | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Pim Berger | M | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | - |
Lee Cooper | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Natalie Berner | F | 34 | 3 anni | |
Leonardo Caló | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Fabian Engelhorn | M | - |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | - |
Andreas Goette | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Robert Scott | M | 70 | 2 anni | |
Juan Carlos Zapata | M | - |
BioMedx Group, Inc.
BioMedx Group, Inc. Medical SpecialtiesHealth Technology BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD. | - |
Guillaume Jetten | M | 52 |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 5 anni |
Taro Inaba | M | 56 |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Zeev Zehavi | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 11 anni |
Gaston Matthyssens | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Joseph Anderson | M | 65 | 1 anni | |
Ute Mercker | F | 57 |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | 9 anni |
Markwin P. Velders | M | 59 |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 4 anni |
Marie Lindner | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Richard E. Armer | M | - | 12 anni | |
Thomas Bengt Eldered | M | 64 |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 5 anni |
Peter Collum | M | - | 3 anni | |
Ted Ingemar Jakob Fjällman | M | 46 |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 5 anni |
Erez Chimovits | M | 60 |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Martin Pfister | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Lior Teitelbaum | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 5 anni |
Jane Griffiths | M | 69 | 3 anni | |
Liana Patt | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 2 anni |
Peter Seiler | M | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | - |
Caitlin Pearson | F | - | 2 anni | |
Maarten de Château | M | 61 |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 5 anni |
Michael Gilman | M | 69 |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Dror Haratz | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Derek Lindsay | M | 62 | 7 anni | |
Neil David Murray | M | 60 | 7 anni | |
Norman Molyneux | M | 68 | 7 anni | |
Claire Solk | F | - | - | |
Dominic Nicholas Jackson | M | - | 2 anni | |
Sarah Gordon-Wild | F | - | 3 anni | |
Karl Hård | M | 62 | 1 anni | |
Phillip John Tottey | M | 62 | 3 anni | |
Iain Ross | M | 71 | 4 anni | |
Joerg Wulfken | M | 64 |
Universität Konstanz
| 3 anni |
Andreas Wiedemann | M | 56 |
Universität Konstanz
| 4 anni |
Asha-Rose Mtengeti Migiro | M | 67 |
Universität Konstanz
| 3 anni |
Frank A. Wetter | M | - |
Universität Konstanz
| 5 anni |
Jane Robertson | M | - | 3 anni | |
Paul Gullery | M | - |
Universität Konstanz
| 6 anni |
Frank Armstrong | M | 67 | 3 anni | |
Peter McPartland | M | 70 | 7 anni | |
Thomas Ingelfinger | M | 63 |
Universität Konstanz
| - |
Georg Denoke | M | 59 |
Universität Konstanz
| 4 anni |
Tom Burt | M | 45 | 3 anni | |
Nicholas Adams | M | 60 | 3 anni | |
Steen Klysner | M | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | 3 anni |
Gordian Kemen | M | - |
Universität Konstanz
| 6 anni |
David Lawrence | M | 61 | 1 anni | |
Andrew Saunders | M | - | 3 anni | |
Peter C. Conzatti | M | - |
Universität Konstanz
| 1 anni |
Walter Rust | M | 67 |
Universität Konstanz
| 3 anni |
Duncan Young | M | - | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 29 | 36.25% |
Germania | 25 | 31.25% |
Israele | 15 | 18.75% |
Paesi Bassi | 10 | 12.50% |
Stati Uniti | 1 | 1.25% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Bernhard Kirschbaum
- Contatti personali